Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Non Small Cell Lung Carcinoma NSCLC 2NSCLC 2Melanoma 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × CP protocol × Clear all
NCT06008106 2024-06-28

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Dermatologic

Melanoma

NCT00111007 2014-10-31

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Bayer

Phase 3 Completed
270 enrolled 15 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡